Casebia Therapeutics

Casebia Therapeutics is a biotechnology startup based in the United States, founded in 2016. Positioning itself as an innovative gene editing company, it is dedicated to discovering and developing curative treatments for genetic diseases. Through a strategic partnership between Bayer and CRISPR Therapeutics, Casebia aims to create breakthrough therapeutics targeting blood disorders, blindness, and congenital heart disease. This unique partnership leverages the strengths of each entity. CRISPR Therapeutics contributes its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer provides its protein engineering expertise and disease know-how. This collaboration represents a significant investment in the development of target delivery systems, focusing on bringing systemic in vivo CRISPR-Cas9 gene editing technology applications to patients. With a focus on targeting severe genetic diseases, Casebia is at the forefront of biotechnological advancement. While specific investment and investor details are not disclosed, the company's strategic partnership and innovative approach position it as a key player in the biotechnology industry, with the potential to revolutionize gene therapy and precision medicine.